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New Directions for Stuck Cholesterol
Niemann-Pick disease type C is caused by a defect in the
movement of unesteriﬁed cholesterol from the late en-
dosomal/lysosomal compartment to the cytosol. Through-
out the body, cholesterol accumulates in these cellular
compartments and ultimately leads to liver dysfunction
and progressive neurological disease. Liu et al. realized
that if they could circumvent the block in cholesterol
movement, perhaps they could alter the disease course.
They did single injections of the cholesterol-binding agent
2-hydroxypropyl-b-cyclodextrin (CYCLO) into 7-day-old
npc1/ mice and found that this agent solubilizes the
cholesterol trapped in the lysosomes and allows it to
proceed to the metabolically active cholesterol pool.
Although CYCLO treatment had no observed effects in
wild-type mice, treatment of npc1/ mice led to signiﬁ-
cant declines in liver sterol concentration and normalized
rates of sterol synthesis. More strikingly, although CYCLO
was rapidly cleared from the body and cholesterol began to
again accumulate in the lysosomal system, the single injec-
tion of the compound at day 7 had observable effects when
the same mice were 49 days old. Treated mice had lower
cholesterol levels in the liver and other organs, better liver
function, and twice as many surviving Purkinje cells in the
cerebellum as did their untreated counterparts. Further,
the single injection led to an approximately 25% increase
in longevity of the npc1/mice. There is still a lot to learn
about the effects of this sterol-binding agent on Niemann-
Pick disease, but CYCLO could be a useful tool to studying
cholesterol trafﬁcking out of the lysosomal system and the
pathogenesis of this devastating disease.
Liu et al. (2009). Proc. Natl. Acad. Sci. USA 106, 2377–
2382. 10.1073/pnas.0810895106.
Plant Model of Triplet Repeat Expansions
Despite the fact that trinucleotide repeat expansions cause
more than a dozen different human neurologic diseases,
we have a very limited understanding of how these repeats
undergo large expansions within a single generation. An
experimental system to study this mutational mechanism
has so far been elusive because a model in which these
mutations are similarly dynamic had not been found.
That is, until the work by Sureshkumar et al. in which
they found a strain ofArabidopsis thaliana that has a growthThe Amedefect resulting from an intronic triplet repeat expansion.
The phenotype in this strain is due to reduced expression
of the gene in which the expansion occurs; overexpression
of the mature RNA in mutant plants rescues the pheno-
type, and all of the 17 spontaneous revertants had reduc-
tions in the trinucleotide repeat length. Modifying factors
seem to have a role in this phenotype, as evidenced by the
fact that a minority of EMS-induced phenotypic revertants
had repeat length reductions. These strains presumably
have second site mutations within genes that inﬂuence
the phenotypic consequences of the repeat expansion.
Sureshkumar et al. (2009). Science 323, 1060–1063.
10.1126/science.1164014.
Rescuing Yeast from Parkinson Disease
Although yeast obviously can’t get Parkinson disease, that
does not mean they can’t be a useful model in which to
study the disease. Proving this, Gitler et al. use yeast to
identify an interaction between two Parkinson genes as
well as an environmental risk factor. Dosage changes and
mutations in a-synuclein cause familial Parkinson disease.
Although this lipid binding protein is clearly involved in
vesicle trafﬁcking, we have a limited understanding of
the pathogenesis of the synucleinopathies, including the
relationship of a-synuclein to other Parkinson genes.
Although yeast lack a clear homolog of a-synuclein,
expression of human a-synuclein causes dose-dependent
toxicity in yeast. Gitler et al. use this simple system to
screen for modiﬁers of this toxicity and here ﬁnd the ﬁrst
genetic connection between a-synuclein and PARK9,
another gene involved in familial Parkinson disease. The
yeast homolog of PARK9 suppressed a-synuclein toxicity
in their screen and also rescued the defect in trafﬁcking
from the ER to Golgi in these cells. The relevance of this
interaction is underscored by the suppression of a-synu-
clein toxicity that was also found with PARK9 homologs
in C. elegans and in rat neurons. Beyond the link between
two parkinsonism genes, the authors also tie this network
to an environmental risk factor for parkinsonism, manga-
nese. Yeast lacking the PARK9 homolog are hypersensitive
to manganese, and Gitler et al. suggest that PARK9 func-
tions as a manganese transporter that protects cells from
exposure to this neurotoxin.
Gitler et al. (2009). Nat. Genet., in press. Published online
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LIS1 Overexpression Affects Brain Development Correction of Methylation Defects by RNAiSometimes too much of a good thing can be almost as bad
as too little. Bi et al. identify duplications around chromo-
some 17p13.3, which corresponds to a region that, when
deleted, is associated with lissencephaly and Miller-Dieker
syndrome. The genes relevant to the deletions are
PAFAH1B1, which encodes LIS1, and YWHAE. The
majority of the seven duplications are de novo, and each
has unique breakpoints. Only one encompasses both
PAFAH1B1 and YWHAE. Phenotypic comparisons indicate
that YWHAE duplications tend to be associated with mac-
rosomia, mild developmental delay, and a shared facial
appearance. Increased dosage of PAFAH1B1, on the other
hand, is associated with failure to thrive, more severe
developmental delay, and microcephaly. In support of
the relevance of the duplications to the phenotype of these
patients, mice that overexpress LIS1 in the developing
brain have smaller brains, along with disorganization in
the ventricular zone that is marked by reductions in cell
polarity and defects in neuronal migration. This work
adds to the number of genomic regions that exhibit
phenotypes when there is either an increased or
a decreased dosage.
Bi et al. (2009). Nat. Genet. 41, 168–177. 10.1038/ng.
302.306 The American Journal of Human Genetics 84, 305–306, MarchSmall RNAs can silence genes in various ways, but we nor-
mally think of them as acting on messenger RNA transla-
tion or stability. But—particularly in plants—RNAi mecha-
nisms can also be used to guide epigenetic modiﬁcations.
Teixeira et al. studied transgenerational remethylation in
Arabidopsis. Mutations in the ATPase chromatin-remodeler
gene DDM1 cause severe loss of DNA methylation overall,
but crosses with wild-type plants can progressively restore
remethylation of many of these sequences over genera-
tions. However, if you look at the demethylated sequences
more speciﬁcally, it turns out that some can be remethy-
lated in this system, but others cannot, and these differ-
ences are consistent over many plant lines. An abundance
of 24 nt RNAs corresponds to the remethylatable
sequences and are crucial to this process; blocking produc-
tion of these siRNAs prevents remethylation. Preventing
transgenerational epigenetic defects is thus another in
the list of functions for RNAi in Arabidopsis. The impor-
tance of this function is illustrated by the fact that trans-
posable elements associated with remethylated sequences
become resilenced when methylation occurs, whereas
those in nonremethylated regions remain active.
Teixeira et al. (2009). Science, in press. Published online
January 29, 2009. 10.1126/science.1165313.13, 2009
